Your session is about to expire
← Back to Search
SAPIEN M3 System for Mitral Regurgitation (SAPIEN M3 EFS Trial)
SAPIEN M3 EFS Trial Summary
This trial will study whether it is safe to implant the SAPIEN M3 System in patients with severe MR, and will also provide information to help plan future clinical studies using this system.
SAPIEN M3 EFS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSAPIEN M3 EFS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SAPIEN M3 EFS Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.Your heart's shape would make it difficult to put in the device or valve correctly.I have kidney problems or am on dialysis.I have liver disease or abnormal liver test results.I am currently pregnant or breastfeeding.It is expected that you will live for less than 12 months.Your heart imaging shows a mass, blood clot, or infection.You have a high risk of blockage in the left ventricular outflow tract.Your heart's pumping ability is less than 30%.My condition cannot be treated with surgery.I've had surgery on my mitral valve that may interfere with new treatments.I have had unexplained blood clots in my veins or lungs more than once.I have not had any heart or carotid artery procedures in the last 30 days.I have a blood disorder affecting my white cells, red cells, or platelets.I have serious heart artery problems that haven't been treated.I have not had active bacterial endocarditis in the last 6 months.I cannot take blood thinning medications due to a health condition.You have heart problems that affect your ability to do physical activities.I haven't been hospitalized for heart failure or needed heart support in the last 30 days.I need a heart valve replacement.I have not had a heart attack in the last 30 days.I am at high risk for heart surgery.I have not had a stroke or mini-stroke in the last 3 months.You have had a heart transplant in the past.You have a mechanical aortic valve implant.I refuse to receive blood transfusions.My heart's right side is not pumping well.You have a high level of MR (mitral regurgitation) in your heart.I have severe, untreatable high blood pressure in my lungs.My heart condition has been stable on medication for at least 2 weeks.
- Group 1: TMVR
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research endeavor currently taking on new participants?
"As indicated on clinicaltrials.gov, the enrolment period for this trial has ended as of June 15th 2022. Originally posted on September 14th 2017, no further participants are needed at present time; however there exists 99 other trials with open recruitment periods."
Are there multiple healthcare facilities currently executing this test?
"Sentara Cardiovascular Research Institution in Norfolk, Virginia, Cedars-Sinai Medical Center Heart Institute in Los Angeles, California and Evanston/ Northshore University in Illinois are three of the ten total centres that are currently enrolling participants for this trial."
Who else is applying?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger